NCT06541314View on ClinicalTrials.gov

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 18, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Ovarian Cancer
Interventions
DRUG

Fluzoparib

Fluzoparib (50mg per capsule) 150mg po bid, with a treatment cycle of 28 days. Administer 2 cycles in total.

Trial Locations (1)

250000

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER